|Bid||9.22 x 1800|
|Ask||9.27 x 1200|
|Day's Range||9.22 - 9.33|
|52 Week Range||4.30 - 13.66|
|Beta (5Y Monthly)||1.31|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 02, 2021 - Nov 08, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.00|
Subscribe to Yahoo Finance Plus to view Fair Value for FLXNLearn more
Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:
On Flexion's (FLXN) third-quarter earnings call, investor focus will be on its updates on earnings and revenues and the upcoming merger with Pacira whereby the latter will acquire the former.